ABCC2

Across TCGA pan-cancer cohorts, ABCC2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ABCC2 data layer compared with 18 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ABCC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ABCC2 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and PDAC are the cancer types where ABCC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.220	0.781	.017	20	view →
LUAD	OS	Median	III,IV	0.285	0.777	.004	18	view →
PDAC	OS	Median	II,III,IV	0.839	0.987	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ABCC2–CCRCC (DFS)

Open the CCRCC breakdown →